north carolina dermatology association 2017 summer meeting · north carolina dermatology...

NORTH CAROLINA DERMATOLOGY ASSOCIATION

2017 SUMMER MEETING

This continuing medical education activity is jointly provided by theNorth Carolina Dermatology Association and

Southern Regional Area Health Education Center SUNDAY HANDOUTS

JULY 7-9, 2017 | OMNI HOMESTEAD RESORT | HOT SPRINGS, VIRGINIA

1

ARTIFICIAL INTELLIGENCE AND MELANOMA

DIAGNOSIS :AM I OUT OFA JOB?

.

Kelly Nelson, MD FAAD

Associate Professor

Department of Dermatology

MDAndersonCancerCenter

http://mdacc.participoll.com

•Noconflicts

Access Seeing it

Melanoma Secondary Prevention

Diagnosticaccuracy

2

Seeing itAccess

Diagnosticaccuracy

Melanoma Secondary Prevention

Dermoscopy

Lancet Oncol 2002;3(3):159‐65; PMID11902502

Dermli e-oto IIPro Plus wi h

ikonD500

$3,995 00

Dermli e Cam®

$2,195.00

Dermli e Foto II Pro

$199500Dermu-e FOTO Sys em

$1 995.00

Dermu e -oroS1150 00

Dermli eDL1

$495 00Dermli e o_1 basic

$299 95

Dermli e Oo iPhone 5/SS

Adapter

$39 00

ikon 1 AW1 with

Mag e iConnect®

$895 00

)

Sony cybersho- DSC-W800 20.1

Dermlite rlOD

$79 95

Dermlite riOD iPhone 6/6S

Adapter

$39 00

3

Automated dermoscopic analysis

MelaFind

Automatedmultispectraldermoscopy analysis

FDAapproved

Expensive

Sn 98.4, Sp9.9

Arch Dermatol 2011;147:188. PMID 20956633

Other diagnostic technologies

• Reflectance confocalmicroscopy

• Optical coherence tomography

• High frequency ultrasound

• Tape stripping

• Spectroscopy

■ Expensive

■ Bulkymachines

■ Challenging imageacquisition

■ True predictive capacity

0A B

Have your patients asked you about this?

A: yes

B: no

Nature. 2017 Feb 2;542(7639):115‐118; PMID 28117445

4

Artificial Intelligence and Image Recognition• Feature extraction +Classification

• Deep Convolutional NeuralNetwork• Overlapping data intake fields

• Convolutional processing

• Deep learning

• GoogleNet Inception v3 CNNarchitecture

Nature. 2017 Feb 2;542(7639):115‐118; PMID 28117445

Nature. 2017 Feb 2;542(7639):115‐118; PMID 28117445

5

Nature. 2017 Feb 2;542(7639):115‐118; PMID 28117445

Nature. 2017 Feb 2;542(7639):115‐118; PMID 28117445

Take Home Points• Secondary Prevention: Patient Access, Seeing it, DiagnosticAccuracy

• Ideal Diagnostic Technology: Portable, Cheap,Accurate

• Validation is essential

1

Clinical and Pathologic Features of Indeterminate Cell Histiocytosis

Resident: Nathaniel Slater, MD

Attending: Natalie Sun, MD

UNC Department of Dermatology

NC Dermatology Summer Meeting

June 9, 2017

2

Our Case

• 55 yo man with a history of HTN and NAFLD presented with an asymptomatic, widespread papular eruption

• Complete ROS pan-negative

• Outside biopsy in June 2016 consistent with Langerhans Cell Histiocytosis (LCH)

• UCSF pathology consultation also favored LCH

3

Exam

2

Exam

4

Exam

5

6

Medical history

• Past medical hx» HTN, NAFLD, prior BCC

• Family hx» No autoimmune

disorders

» Mother: breast ca, 70s

» Brother: Hodgkin’s, 40s

» Pt is 1 of 10 children, no other FH of cancer

• Social hx» Environmental engineer,

married with 12yo child.

• Meds» Irbesartan 150mg daily

» Vascepa (rx fish oil) daily

» Omeprazole 40mg daily

» Sildenafil 100mg prn

• NKDA

3

7

Workup unrevealing for systemic diseasePET CTNo extra-cutaneous disease

Bone marrow biopsy

LabsAlk Phos 123 (H); CMP, CBC, ESR, LDH, IgG/A/M, Ferritin, Uric acid, U/A unremarkable

Normocellularmarrow with no evidence of LCH, langerinnegative.

No immuno-phenotypic

abnormalities on

flow cytometry

Single-system Cutaneous LCH?• Isolated skin disease is rare in adults

• Clinical manifestations: highly variable spectrum reported» Severe intertriginous or seborrheic dermatitis-like,

papulopustular, xanthomatous, purpuric, hemorrhagic, pigmented variants reported (Querings et al., Cardoso et al.)

• Course: highly variable, unpredictable» Numerous indolent cases reported

» Potential for persistence or progressive disease

• Gamut of treatments reported (mostly as case reports):

8

9

H&E c/w LCH

Top Right: low powerLeft, 20XBottom Right, 40X

4

Immunophenotype

10

CD1a

CD68

S100

Negative for:• Cytokeratin• Tryptase• Melan-A• Langerin (CD207)

Immunohistochemistry of Histiocytoses

11

Bolognia et al.

Dx: Indeterminate Cell Histiocytosis (ICH)

• Consistent with LCH» H&E c/w with LCH;

strong and diffuse CD1a positivity

» CD68+ and focal S100 not specific either way

• Favoring ICH» Langerin-

» Lack of epidermotropism, lack of eosinophils

» Clinical picture most consistent with reported cases of ICH

12

CD1a S100 CD68 Birbeckgranule

Langerin(CD207)

FactorXIIIa

LCH + + - / + + + -

ICH + + (or focal) + - - -

5

What Is ICH?• Enigmatic entity, displays LCH markers (CD1a; S100

which can be more focal), but also displays dermal histiocytic markers (CD68)

• Does not display Birbeck granules » Or Langerin (CD207)

• Somewhat controversial entity (< 50 cases reported, some have questioned whether this represents immature or de-differentiated LCH vs variant of non-LCH)» Multiple authors have suggested a spectrum between

Langerhans and non-Langerhans histiocytoses

» First described in 1985, incorporated into WHO classification in 2006

13

Clonality

• LCH » BRAFV600E in

approximately ½ of cases

• ICH » No BRAF mutation

» Clonal translocation in 3 of 4 ICH cases by next-gen sequencing and FISH

» Evidence for ICH as its own clonal entity

14

Clinical Features of ICH• Firm, red, yellow, or red-brown papules

• Isolated and (more commonly) generalized variants

• Predominantly affects adults; favors trunk and extremities

• Most without epidermal change (minimal epidermotropism)

• Clinical ddx: generalized eruptive histiocytoma, juvenile xanthogranuloma, congenital self-healing reticulohistiocytosis, PLC

• Behaves more like non-LCH / reactive macrocytic process» Most cases self-limited or non-progressive

» Largest series (18 pts): most with stable disease, 2 with slow cutaneous progression, 2 developed systemic dz

» Several reports associated with leukemia or low-grade B cell lymphoma 15

6

Additional Images of ICH

16

Logemann et al.

Zerbini et al.

Tardio et al.

Management of ICH• Case reports of response to: observation, UVB (3 cases

with good response), PUVA, low-dose MTX, isotretinoin, thalidomide, systemic anti-neoplastics

17

12 months of NB-UVB; Logemann et al.

Summary• Indeterminate cell histiocytosis is an indolent neoplastic vs

clonal reactive entity

• H&E similar to LCH; CD1a+, S100+ (focal), CD68+, Langerin (CD207) -

• Typically spares skin folds, without epidermal change

• Most cases self-limited or non-progressive, supporting conservative management» Our patient’s case cleared after UVB phototherapy

• Clinical follow-up indicated as there are a few reports of progressive disease or associated lymphoproliferative malignancy

18

7

References• 1. Sun W-G, Zhong L-S, Chen H. A Case of Adult Generalized Cutaneous Langerhans Cell Histiocytosis. Ann Dermatol.

2016;28(2):262-264. doi:10.5021/ad.2016.28.2.262.

• 2. Brown RA, Kwong BY, McCalmont TH, et al. ETV3-NCOA2 in indeterminate cell histiocytosis: clonal translocation supports sui generis. Blood. 2015;126(20):2344-2345. doi:10.1182/blood-2015-07-655530.

• 3. Calatayud M, Güell JL, Gris O, Puig J, Arrondo E, Huguet P. Ocular involvement in a case of systemic indeterminate cell histiocytosis: a case report. Cornea. 2001;20(7):769-771. http://www.ncbi.nlm.nih.gov/pubmed/11588435. Accessed October 22, 2016.

• 4. Campanati A, Simonetti O, Marconi B, et al. Purely cutaneous Langerhans’ cell histiocytosis in an adult woman. Acta Derm Venereol. 2009;89(3):299-301. doi:10.2340/00015555-0614.

• 5. Cardoso JC, Cravo M, Cardoso R, et al. Langerhans cell histiocytosis in an adult: good response of cutaneous lesions to acitretin. Clin Exp Dermatol. 2010;35(6):627-630. doi:10.1111/j.1365-2230.2010.03784.x.

• 6. Daoud MS, Dahl PR, Dicken CH, Phyliky RL. Indeterminate cell histiocytosis treated successfully with 2-chlorodeoxyadenosine.Cutis. 1997;59(1):27-31; quiz 32. http://www.ncbi.nlm.nih.gov/pubmed/9013068. Accessed October 22, 2016.

• 7. Ghanadan A, Kamyab K, Ramezani M, et al. Erratum: Indeterminate Cell Histiocytosis: Report of a Case. Acta Med Iran. 2015;53(9):593. http://www.ncbi.nlm.nih.gov/pubmed/26553091. Accessed October 22, 2016.

• 8. Ghanadan A, Kamyab K, Ramezani M, et al. Indeterminate cell histiocytosis: report of a case. Acta Med Iran. 2014;52(10):788-790. http://www.ncbi.nlm.nih.gov/pubmed/25369016. Accessed October 22, 2016.

• 9. Logemann N, Thomas B, Yetto T. Indeterminate cell histiocytosis successfully treated with narrowband UVB. Dermatol Online J. 2013;19(10):20031. http://www.ncbi.nlm.nih.gov/pubmed/24139371. Accessed October 22, 2016.

• 10. Oh CW, Ivan D, Curry JL, et al. A case of indeterminate dendritic cell tumor presenting with leonine facies. J Cutan Pathol. 2016;43(2):158-163. doi:10.1111/cup.12611.

• 11. O’Malley DP, Agrawal R, Grimm KE, et al. Evidence of BRAF V600E in indeterminate cell tumor and interdigitating dendritic cell sarcoma. Ann Diagn Pathol. 2015;19(3):113-116. doi:10.1016/j.anndiagpath.2015.02.008.

• 12. Park L, Schiltz C, Korman N. Langerhans cell histiocytosis. J Cutan Med Surg. 16(1):45-49. http://www.ncbi.nlm.nih.gov/pubmed/22417995. Accessed October 18, 2016.

• 13. Querings K, Starz H, Balda B-R. Clinical spectrum of cutaneous Langerhans’ cell histiocytosis mimicking various diseases. Acta Derm Venereol. 2006;86(1):39-43. doi:10.2340/00015555-0003.

• 14. Rosenberg AS, Morgan MB. Cutaneous indeterminate cell histiocytosis: a new spindle cell variant resembling dendritic cell sarcoma. J Cutan Pathol. 2001;28(10):531-537. http://www.ncbi.nlm.nih.gov/pubmed/11737523. Accessed October 22, 2016.

19

References• 15. Tardío JC, Aguado M, Borbujo J. Self-regressing S100-negative CD1a-positive cutaneous histiocytosis. Am J Dermatopathol.

2013;35(4):e57-9. doi:10.1097/DAD.0b013e31827adc72.

• 16. Varga E, Korom I, Polyánka H, et al. BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis. J Eur Acad Dermatol Venereol. 2015;29(6):1205-1211. doi:10.1111/jdv.12792.

• 17. Vasef MA, Zaatari GS, Chan WC, Sun NC, Weiss LM, Brynes RK. Dendritic cell tumors associated with low-grade B-cell malignancies. Report of three cases. Am J Clin Pathol. 1995;104(6):696-701. http://www.ncbi.nlm.nih.gov/pubmed/8526215. Accessed October 22, 2016.

• 18. Wang C-H, Chen G-S. Indeterminate cell histiocytosis: a case report. Kaohsiung J Med Sci. 2004;20(1):24-30. doi:10.1016/S1607-551X(09)70080-4.

• 19. Wang P, Wang X, Hong J, Wang Z. Extensive cutaneous Langerhans cell histiocytosis in an elderly woman. J Dermatol. 2011;38(8):794-797. doi:10.1111/j.1346-8138.2010.01098.x.

• 20. Wood GS, Hu CH, Beckstead JH, Turner RR, Winkelmann RK. The indeterminate cell proliferative disorder: report of a case manifesting as an unusual cutaneous histiocytosis. J Dermatol Surg Oncol. 1985;11(11):1111-1119. http://www.ncbi.nlm.nih.gov/pubmed/3902927. Accessed October 22, 2016.

• 21. Yin R, Zheng W, Yang X, Hao F. Recurrent generalized indeterminate cell histiocytosis: a case report. J Am Acad Dermatol. 2010;63(1):e3-5. doi:10.1016/j.jaad.2009.10.010.

• 22. Zerbini MCN, Sotto MN, de Campos FPF, et al. Indeterminate cell histiocytosis successfully treated with phototherapy. Autops case reports. 6(2):33-38. doi:10.4322/acr.2016.038.

20

1

A Case of Gemcitabine-associated “Pseudocellulitis”Sean McGregor, DO, PharmD

Dermatology Resident, PGY-2

Wake Forest University School of Medicine


Wake Forest Baptist Medical Center

History

• HPI: Patient is a 62 year-old female

− Stage IIB (T1N1M0) mixed neuroendocrine and adenocarcinoma of the pancreas

− Status post pylorus-sparing Whipple procedure

− Currently on single agent gemcitabine chemotherapy

− Developed fever, chills, and bilateral lower extremity swelling and redness 5 days after first dose of chemotherapy (1,000 mg/m2)

• Dermatology was consulted regarding bilateral lower extremity cellulitis


History

• Past Medical History− HTN, DM, HLD, and CVA

• Past Surgical History− Pylorus-sparing Whipple procedure

• Social History− Former smoker (45 pack-year history)

• Allergies− NKDA

2


History

• Current medications− Amlodipine 10 mg PO daily

− Gabapentin 300 mg PO TID

− Insulin detemir 10 units SQ daily

− Metoprolol tartrate 12.5 mg PO BID

− Pancrealipase 24,000 units PO TID

− Simvastatin 40 mg PO daily

− Pantoprazole 40 mg PO daily

− Piperacillin/Tazobactam 3.375 g IV Q8H


Physical Examination• Vital Signs: Temp: 99.7 (Tmax 101.3); BP: 145/72

mmHg; HR: 80 BPM; RR: 20/min; O2: 95% RA

Figure 1. Well demarcated erythema over distal lower extremities with 2+ lower extremity edema


Labs and Imaging

• WBC: 6.7 x 103/mm3

• HgB: 7.9 g/dL

• Hct: 24.6%

• PLT: 272,000/mm3

• Na: 134 mEq/L

• K: 4.2 mEq/L

• SCr: 0.48 mg/dL

• Glu: 232 mg/dL

• CT C/A/P− No evidence of pneumonia,

intra-abdominal abscess, or other infectious foci

• Venous Duplex US BLE− Negative for DVT

• Blood cultures− Negative x2

3


Assessment and Plan

• Differential Diagnosis− Stasis dermatitis

− Sclerosing panniculitis

− Non-purulent cellulitis

− Opportunistic (i.e. fungal/AFB) infection

− Cutaneous reaction to gemcitabine?

• Plan− Punch biopsy (4 mm) sent for H&E and tissue culture


Results

Figure 3. H&E, 200X; Mixed cellular infiltrate with neutrophils

Figure 4. H&E, 400X; Mixed cellular infiltrate with neutrophils

Figure 2. H&E, 10X; sparse inflammatory infiltrate


Discussion

• Gemcitabine is a pyrimidine antimetabolite− MOA: Inhibition of DNA synthesis

Inhibits DNA polymerase and ribonucleotide reductase

Cell cycle-specific for the S-phase and blocks cellular progression at G1/S phase

• Active against solid-organ malignancies

• Adverse reactions typically include nausea, vomiting, anemia, and neutropenia

• Cutaneous reactions are less common, but have been reported (up to 30%)

4


Discussion

• “Pseudocellulitis” is a broad term used to classify a subset of cutaneous reactions− Radiation recall dermatitis

− Erysipeloid eruptions

− Scleroderma-like eruptions

− Lipodermatosclerosis-like eruptions

• Pubmed search of “gemcitabine” and “pseudocellulitis” reveals 11 case reports

• Recent case series in JAAD proposed re-classification of the terminology− Acute Lipodermatosclerosis (ALDS)-like eruption


Discussion

• Mittal and Levanthal. JAAD Case Reports.2017;3:190-5.− A 76 year-old male with pancreatic cancer on adjuvant

gemcitabine

− New-onset erythema, edema and pain in bilateral lower extremities after 5th dose

− Afebrile and no leukocytosis

− Improved after topical clobetasol and compression therapy


Discussion

• Strouse and Epperla. J Oncol Pharm Practice. 2017;23(2):157-160.− A 62 year-old female with metastatic pancreatic cancer on

gemcitabine

− New-onset erythema, edema and pain in bilateral lower extremities after 2nd dose

− Had history of chronic edema in lower extremities

− Afebrile but leukocytosis present

− Biopsy showed neutrophilic infiltration

5


Discussion• Asemota, Reid, and Kovarik. JAAD Case

Reports.2015;1:178-81. − A 77 year-old male with stage IV NSCLC status post

radiation and carboplatin/pemetrexed chemotherapy on gemcitabine

− Acute onset bilateral lower extremity erythema after 3rd dose (similar reactions after prior doses)

− Afebrile and no leukocytosis

− Biopsy showed edema and sparse mixed inflammation with lymphocytes, neutrophils, and rare esosinophils

• Similar cases of radiation-recall dermatitis and “pseudocellulitis” over areas of ascities reported


Discussion• Mechanism of reaction is unclear

− Increased vascular permeability

− Direct endothelial damage

− Release of vasoactive cytokines

• Widely distributed in tissues− Vd ranges from 50-370 L/m2 (depending on infusion time)

− Lipophilic and readily diffuses into extracellular compartment

• Decreased clearance and accumulation in cutaneous and subcutaneous tissues with resultant local toxicity?


Discussion

• Typically occurs on the lower extremities

• Patients often have bilateral involvement

• Develops within 2-5 days of gemcitabine infusion

• Leukocytosis and fever are usually absent− However, both have been reported

• May be associated with peripheral edema− Patients with underlying venous stasis may have higher

risk of ALDS-like reaction

6


Discussion

• Problem — clinical confusion regarding diagnosis

− Overlapping clinical features with cellulitis

− Gemcitabine independently associated with fever (40%) and peripheral edema (15-20%)

− Patients are often treated with antibiotics for presumed cellulitis


Discussion

• Treatment− Topical corticosteroids

− Compression therapy

− Leg elevation

− NSAIDs

− Discontinuation of gemcitabine?

Most patients continue treatment despite reaction

Reaction usually self-limited

Patients typically improve after 1-2 weeks

Recurrence usually occurs in similar distribution


Discussion

• Condition is underrecognized and underreported

• Recognition is important− Avoids interruption in treatment

− Avoids unnecessary use of antibiotics

− Avoids unnecessary hospitalization

− Avoids unnecessary costs and complications

• Our recommendations:− Triamcinolone 0.1% ointment BID

− Leg elevation

− Compression therapy

7


References• 1: Mittal A, Leventhal JS. Gemcitabine-associated acute lipodermatosclerosis-like eruption: An underrecognized phenomenon. JAAD Case Rep.

2017 Apr 14;3(3):190-195.doi: 10.1016/j.jdcr.2017.02.014. eCollection 2017 May. PubMed PMID: 28443306;PubMed Central PMCID: PMC5394206.

• 2: Strouse C, Epperla N. A rash diagnosis: Gemcitabine-associated pseudocellulitis. J Oncol Pharm Pract. 2017 Mar;23(2):157-160.doi10.1177/1078155216635852. Epub 2016 Jun 23. PubMed PMID: 26946530.

• 3: Curtis S, Hong S, Gucalp R, Calvo M. Gemcitabine-Induced Pseudocellulitis in a Patient With Recurrent Lymphedema: A Case Report and Review of the Current Literature. Am J Ther. 2016 Jan-Feb;23(1):e321-3. doi:10.1097/MJT.0000000000000024. Review. PubMed PMID: 24451298.

• 4: Ruiz-Casado A, Gutiérrez D, Juez I. Erysipeloid rash: A rare adverse event induced by gemcitabine. J Cancer Res Ther. 2015 Oct-Dec;11(4):1024. doi:10.4103/0973-1482.148711. PubMed PMID: 26881588.

• 5: Dasanu CA, Bockorny B. Recurrent pseudocellulitis due to gemcitabine: underrecognized and underreported? J Oncol Pharm Pract. 2015 Oct;21(5):377-9. doi: 10.1177/1078155214531610. Epub 2014 Apr 24. PubMed PMID: 24769519.

• 6: Asemota E, Reid E, Kovarik C. Gemcitabine-induced pseudocellulitis in a patient with non-small cell lung carcinoma. JAAD Case Rep. 2015 Jun 8;1(4):178-81. doi: 10.1016/j.jdcr.2015.04.007. eCollection 2015 Jul. PubMed PMID: 27051723; PubMed Central PMCID: PMC4808723.

• 7: Obeid KM, Venugopal AA. Gemcitabine-associated "pseudocellulitis" and "pseudosepsis": a case report and review of the literature. Am J Ther. 2013 Jan;20(1):118-20. doi: 10.1097/MJT.0b013e3182204ffe. Review. PubMed PMID 21768869.

• 8: Singh A, Hampole H. Gemcitabine associated pseudocellulitis. J Gen Intern Med. 2012 Dec;27(12):1721. doi: 10.1007/s11606-012-2101-x. Epub 2012 Jun 14. Erratum in: J Gen Intern Med. 2013 Apr;28(4):600. PubMed PMID: 22696254; PubMed Central PMCID: PMC3509303.

• 9: Korniyenko A, Lozada J, Ranade A, Sandhu G. Recurrent lower extremity pseudocellulitis. Am J Ther. 2012 Jul;19(4):e141-2. doi: 10.1097/MAJ.0b013e318245fdaa. PubMed PMID: 22772033.

• 10: Tan DH, Bunce PE, Liles WC, Gold WL. Gemcitabine-related "pseudocellulitis": report of 2 cases and review of the literature. Clin Infect Dis. 2007 Sep 1;45(5):e72-6. Epub 2007 Jul 20. Review. PubMed PMID: 17682983.

• 11: Zustovich F, Pavei P, Cartei G. Erysipeloid skin toxicity induced by gemcitabine. J Eur Acad Dermatol Venereol. 2006 Jul;20(6):757-8. PubMed PMID:16836522.

• 12: Kuku I, Kaya E, Sevinc A, Aydogdu I. Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma. J Eur Acad Dermatol Venereol. 2002 May;16(3):271-2. PubMed PMID: 12195570.


Thank you!Questions?

1

A rare cause of breast ulceration:diffuse dermal angiomatosis

July 9, 2017

Diana Norton, MDAngelica Selim, MD, & Claude Burton, MD

Clinical Presentation

70 yo lady with four months of painful non-healing ulcerations on the breast

Past medical history

- Severe obesity, BMI 47 with macromastia

- Venous insufficiency—leg ulcers x1 year and varicose veins s/p radio frequency ablation

- Former smoker

- No breast cancer

2

Differential diagnoses

MALIGNANCY Trauma

- Bras, seatbelts

- Radiation

Vascular

- Pyoderma gangrenosum

- Diffuse dermal angiomatosis

Infection

- Cellulitis, mastitis

- Zoster

Diffuse dermal angiomatosis

• Benign vascular disorder

• Cutaneous reactive angiomatosis

• Causes:– Local ischemia hypoxic stimulus

increased vascular endothelial growth factor

– Vascular occlusion emboli neoangiogenesis

Locations

• Lower extremities in severe atherosclerotic disease (majority of cases)

• Forearm adjacent to fistula in dialysis patient

• Pendulous breasts of women

3

Reports in the literature

Biopsy results

• Diffuse proliferation of endothelial cells lining capillary sized vessels in the reticular dermis

• Our patient:

– Acanthosis, dermal edema, chronic inflammation

4

Largest case series

Risk factors

5

Treatment options

Isotretinoin 50mg daily

Taper over several months

Our patient

Diligent wound care with ulcer resolution in 2 months without recurrence on 5 month follow up

Summary

• Diffuse dermal angiomatosis is a rare and poorly studied disease

• Consider in women with pendulous breasts and smoking history

• Biopsy may be helpful if it reveals proliferating vessels in the dermis

• No consensus on therapy—wound care, isotretinoin, surgery, revascularization

References1. Adams BJ, Goldberg S, Massey HD, Takabe K. A cause of unbearably painful breast, diffuse dermal angiomatosis. Gland Surg. 2012 Aug 1;1(2)PubMed PMID: 24353983; NIHMSID: NIHMS470113; PubMed Central PMCID: PMC3864042.2. Kimyai-Asadi A, Nousari HC, Ketabchi N, Henneberry JM, Costarangos C. Diffuse dermal angiomatosis: a variant of reactive angioendotheliomatosis associated with atherosclerosis. J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):257-9. PubMed PMID: 10025757.3. Requena L, Fariña MC, Renedo G, Alvarez A, Yus ES, et al. Intravascular and diffuse dermal reactive angioendotheliomatosis secondary to iatrogenic arteriovenous fistulas. J Cutan Pathol. 1999 Mar;26(3):159-64. PubMed PMID: 10235383.4. Reusche R, Winocour S, Degnim A, Lemaine V. Diffuse dermal angiomatosis of the breast: a series of 22 cases from a single institution. Gland Surg. 2015 Dec;4(6):554-60. PubMed PMID: 26645009; PubMed Central PMCID: PMC4647012.5. Rongioletti F, Rebora A. Cutaneous reactive angiomatoses: patterns and classification of reactive vascular proliferation. J Am Acad Dermatol. 2003 Nov;49(5):887-96. PubMed PMID: 14576670.6. Sriphojanart T, Vachiramon V. Diffuse Dermal Angiomatosis: A Clue to the Diagnosis of Atherosclerotic Vascular Disease. Case Rep Dermatol. 2015 May-Aug;7(2):100-6. PubMed PMID: 26120304; PubMed Central PMCID: PMC4478308.7. Tollefson MM, McEvoy MT, Torgerson RR, Bridges AG. Diffuse dermal angiomatosis of the breast: clinicopathologic study of 5 patients. J Am Acad Dermatol. 2014 Dec;71(6):1212-7. PubMed PMID: 25264238.8. Villa MT, White LE, Petronic-Rosic V, Song DH. The treatment of diffuse dermal angiomatosis of the breast with reduction mammaplasty. Arch Dermatol. 2008 May;144(5):693-4. PubMed PMID: 18490610.

1

The Clinical Relevance of “Atypia” in a Dermatopathology Report

Paul B Googe, MD

Professor and Laboratory Director

UNC Dermatopathology Laboratory


Atypia

• Abnormalities in pattern of growth, anatomic location

• Cytological abnormalities

– Cell size

– Nuclear configuration

– Nuclear to cytoplasmic ratio

– Cytoplasmic changes

– Nucleoli

2

Atypia

• Mitotic activity

• Necrosis

• Size of tumor

• Staining characteristics

– Unusual or aberrant immunohistochemical staining results

• Cytokeratin positivity in melanoma or sarcoma

• Cytokeratin 20 negative Merkel cell carcinoma

April June

July

3

Atypia

• Difficulty in classification or ability to recognize a neoplasm

– lack of familiarity

– uncertainty

• Pathologic findings inconsistent with clinical, imaging, past medical history or laboratory findings

Definitions:

• Benign – may persist and enlarge, may clinically reappear if incompletely removed, but not expected to be locally destructive or metastasize or be fatal

• Atypia – same as benign

– In some tumor constructs may relate to propensity for local recurrence or persistence and/or limited metastatic phenomenon

• Malignant – May be locally destructive, metastasize or be fatal

4

Important observations:

– Benign tumors can recur

– Well described phenomenon of some types of benign tumors that show regional lymph node presence

• Cellular blue nevi

• Congenital nevi

• Hidradenoma

– Malignant tumors do not necessarily metastasize and are not uniformly fatal

– Heterogeneity of neoplasia with regard to lethal potential

– Genotype of a neoplasm may or may not be predictive of lethal potential

– Pathologic findings may provide information that is of prognostic use based on statistics, but prognosis of an individual may simply not be accurately predicted in some forms of neoplasia

Recurrent/Persistent Clear Cell Hidradenoma

2005 2011 2012

“Atypia” in benign neoplasms

• Dermatofibroma

• Seborrheic keratosis

• Melanocytic nevi

• Hidradenoma

• Pilar tumor

5

“Atypical” neoplasms that have benign behavior

• Dysplastic nevi

• Atypical spitz nevus

• Atypical proliferating pilar tumor

• Atypical pilomatricoma

• Atypical hidradenomas

• Atypical cellular blue nevus

• Atypical intradermal smooth muscle neoplasm

What are dysplastic nevi?

• Dysplastic nevi are benign melanocytic neoplasms which have clinical and histological attributes that resemble what may be seen in early or evolving melanoma.

• Dysplastic nevi occur sporadically and in kindreds with familial melanoma.

• Dysplastic nevi have a histological pattern with certain, consistent features

Dysplastic Nevus

Major Criteria

1. Basilar proliferation of melanocytes, often with nesting, usually extending beyond a dermal nevic component, if present

2. Melanocytic atypism

6

Melanocytic atypism in dysplastic nevi

• Increase in cell size

• Increase in size of nucleus

• Nuclear hyperchromasia

• Shape of nucleus

• Cytoplasmic alterations – pigment granules

Minor Criteria

1. Inflammatory infiltrate

2. Increased vascularity with evidence of endothelial‐cell hypertrophy

3. Concentric eosinophilic fibrosis and/or lamellar fibroplasia

4. Bridging of rete by nests of melanocytes

Inflammatory Infiltrate

7

Increased vascularity

Concentric eosinophilic fibrosis

Lamellar fibroplasia

8

Bridging of rete by nests of melanocytes

DYSPLASTIC NEVUS, DIAGNOSTIC TERMINOLOGY, HISTOPATHOLOGIC

after Clark et al, WHO

• nevus with features of a dysplastic nevus

• dysplastic nevus with mild atypia

• dysplastic nevus with moderate atypia

• dysplastic nevus with severe atypia

N.I.H. Consensus Statement

• nevus with architectural disorder

• nevus with architectural disorder and mild melanocytic atypia

• nevus with architectural disorder and moderate melanocytic atypia

• nevus with architectural disorder and severe melanocytic atypia

Ackerman“Clark’s nevus”

Clinical attributes of dysplastic nevi

• Larger than 5 mm

• Variability in contour

• Variability in color

9

Treatment of Dysplastic Nevus

Features of, Mild atypia or Moderate atypia

‐ No re‐excision unless

– Partial sampling

– Concern for malignancy remains

Severe Atypia

– Complete removal

Atypical Spitz Nevus

Atypical cellular blue nevus

10

Smooth muscle actin

Atypical intradermal Smooth Muscle Neoplasm

“Atypical” neoplasms that have malignant potential or are early patterns of malignancy

• Atypical fibroxanthoma

• Atypical lentiginous melanocytic hyperplasia

• Atypical vascular proliferation after radiation therapy

11

Atypical Fibroxanthoma

• Dermal based neoplasm• Sun damaged skin older people• Head and neck• Microscopically highly malignant, sarcoma‐like• Infrequently recur locally• Rarely metastasize• Small diameter ( typically 1 cm or so)• Nonpigmented, sometimes ulcerated• No horn• Differential diagnosis: poorly differentiated SCC, desmoplastic melanoma

12

CK AE1/AE3

Vimentin

13

Clear cell Atypical fibroxanthoma

VimentinCD10

Case: Clinical History

• 73 year old white male presents to dermatology clinic for two new lesions developing on vertex of head (4/6/2011)

• 2 lesions measuring 1.5 cm each– red, nodular, with smooth borders

• Hx significant for multiple SCCs• Hx of Radiation Treatment to the Right side of head x 30

– Unknown amounts of occupational radiation exposure

• Biopsy of both lesions performed and submitted for pathology

14

Consistent with Aypical Fibroxanthoma (AFX)

• Spindle cell lesion in the dermis

• No perivascular or perineural invasion

• No necrosis

• No invasion into subcutis

• High mitotic activity with pleomorphic nuclei

Clinical History

• Patient returns to dermatology clinic 20 months later (11/17/2011)

– 4 recurrent nodules on vertex of head

• Clinical exam is similar to the previous presentation

• Pathology diagnosis is AFX

– Similar histology to previous biopsy

• Patient is referred for wide local excision

15

Satellite Metastasis

16

Immunohistochemistry

• Negative staining

– AE1/3, S100, Melan‐A, Tyrosinase, SMA, Desmin, CD34, CD31, CK5/6, 34be12, p63, Sox 10

• Positive staining

– Vimentin, Procollagen, CD10

AFX with subcutaneous involvement, present in deep margin = pleomorphic dermal sarcoma

17

Pleomorphic Dermal Sarcoma

• Term proposed by C.D. Fletcher

• Miller K, Goodlad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol. 2012 Sep;36(9):1317‐26

Pleomorphic Dermal Sarcoma

• Differentiated histologically from AFX by– Necrosis

– Ulceration

– Deep subcutaneous invasion

– Lymphovascular invasion

– Perineural invasion

• Significant overlap of clinical picture, histology, and prognosis with AFX• May be considered a part of a spectrum

Atypical Fibroxanthoma (small)vs

Pleomorphic dermal sarcoma (big)

• Atypical fibroxanthoma

• Dermal

• Typically less than 2 cm

• Undifferentiated stromal neoplasm

• Tert mutation

• Sometimes recur

• Rarely metastasize

• Pleomorphic dermal sarcoma

• Subcutaneous

• 2 cm or greater

• Vascular/perineural invasion

• Undifferentiated stromal neoplasm

• Tert mutation

• Sometimes metastasize

18

Recurrent AFX

19

No Residual TumorMargins Free

Patient/Tumor Features Associated With Bad Outcome With Skin Cancers

• Advancing age

• Immunosuppression (organ transplant)

• Chronic lymphocytic leukemia

• Large tumor diameter, deep/thick invasion, perineural invasion

• Head and neck location

• Local recurrence

20

Questions to consider in “atypical” cases

• Is the neoplasm properly classified ?• Is the atypia a recognized phenomenon to occur in the class of neoplasm specified?

• Was the lesion well sampled and evaluable?• How many special stains or studies were used to arrive at the conclusion?

• Is there a pertinent reference in the literature that substantiates the classification used?

• What are the consequences to patient management?• Is there potential for bad or unexpected outcome?

Grading and Staging of Neoplasia

• Histologic grade – How malignant does it look under microscope?

• High grade – bad – high risk for metastasis and death• Low grade – good – may recur locally, show limited metastatic potential and are unlikely to cause death

• Intermediate grade ‐ ? – depends on type of tumor

• Staging– How big? Volume of tumor– Anatomic compartment– Regional metastasis– Distant metastasis

Trust, but Verify

Management of “Atypical” Neoplasms

21

Management of “Atypical” Neoplasms

• Complete removal with a margin of normal tissue

• Thorough pathologic analysis

• Follow up» Clinical evaluation of regional lymph nodes

» Consider imaging

» Specialty clinic or specialist to assist in follow up care

• Repeat tissue sampling of potential recurrences or metastases

• Reassure patient and educate » Enlist patient/family to help watch for reappearance or new

lesions

» Don’t make promises6/23/2017 61

north carolina dermatology association 2017 summer meeting · north carolina dermatology...

Documents